Evaluation of [18F]MK-9470 as a Brain Tracer of Cannabinoid-1 Receptor in Parkinson’s Disease and Healthy Subjects

Brief Summary

Official Title: “Evaluation of [18F] MK-9470 and PET as a Marker of Cannabinoid-1 Receptor Activity in Subjects With Parkinson Disease Compared With Healthy Controls”

The purpose of this study is to assess MK-9470 Positron Emission Tomography (PET) imaging as a tool to evaluate the activity of the CB-1 receptor in the brain.

  • Study Type: Interventional
  • Study Design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
  • Study Primary Completion Date: May 2013

Detailed Clinical Trial Description

The underlying goal of this study is to assess MK-9470 PET imaging as a tool to evaluate the activity of the CB-1 receptor in the brain of Parkinson's Disease (PD) research participants.

Interventions Used in this Clinical Trial

  • Drug: [18F]MK-9470
    • Subjects will be injected with 10 mCi, and not to exceed 11 mCi (not >10% of 10 mCi limit)of [18F]MK-9470, followed by PET imaging.

Arms, Groups and Cohorts in this Clinical Trial

  • Experimental: Assess [18F]MK-9470 and PET imaging
    • To Assess [18F]MK-9470 and PET imaging

Outcome Measures for this Clinical Trial

Primary Measures

  • Dynamic uptake and washout of [18F]MK-9470
    • Time Frame: Approximately 2 years
      Safety Issue?: No

Secondary Measures

  • To acquire safety data
    • Time Frame: Approximately 2 years
      Safety Issue?: Yes

Criteria for Participation in this Clinical Trial

Early PD Subjects

Inclusion Criteria

  • The participant is 30 years or older.
  • Written informed consent is obtained.
  • Participants have a diagnosis of PD (based on UK Brain Bank Criteria) within the past 2 years.
  • Modified Hoehn and Yahr stages 1-2.
  • No evidence of dyskinesia by history or clinical examination
  • For females, non-child bearing potential or a negative urine or blood pregnancy test on day of [18F]-MK-9470 injection.

Advanced PD subjects

Inclusion Criteria

  • The participant is 30 years or older.
  • Written informed consent is obtained.
  • Participants have a diagnosis of PD (based on UK Brain Bank Criteria) of at least 5 years duration.
  • Modified Hoehn and Yahr stages 1-4.
  • No evidence of dyskinesia by history or clinical examination
  • For females, non-child bearing potential or a negative urine or blood pregnancy test on day of [18F]-MK-9470 injection.

Subjects who have a clinical diagnosis of advanced PD with dyskinesia will be recruited for this study.

ePD subjects

Inclusion Criteria

  • The participant is 30 years or older.
  • Written informed consent is obtained.
  • Participants have a diagnosis of PD (based on UK Brain Bank Criteria) of at least 5 years.
  • Modified Hoehn and Yahr stages 1-4.
  • Evidence of dyskinesia either by history or clinical examination
  • For females, non-child bearing potential or a negative urine or blood pregnancy test on day of [18F]-MK-9470 injection.

PD (all stages- e-PD, aPD, aPD-dys)Subject Selection. Subjects who have a clinical diagnosis of ePD, aPD, aPD-dys will be recruited for this study.

All PD subjects

Exclusion Criteria

  • The subject has a clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness
  • The subject has any disorder that may interfere with drug absorption, distribution, metabolism, or excretion.
  • The patient has evidence of unstable gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, pulmonary, or other disorder or disease.
  • Evidence of a stroke or mass lesion in a clinically relevant area that may interfere with the imaging outcome measure
  • Subjects with radiation exposure above acceptable levels
  • Pregnancy

Healthy Control Subject Selection: subjects who have no neurological disease will be recruited for this study.

Healthy control subjects

Inclusion Criteria

  • The participant is 18 years or older.
  • Written informed consent is obtained.
  • Negative history of neurological or psychiatric illness based on evaluation by a research physician.
  • For females, non-child bearing potential a negative urine or blood pregnancy test on day of [18F]-MK9470 injection.

Exclusion Criteria

  • The subject has a clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness.
  • The subject has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease.
  • The subject has any disorder that may interfere with drug absorption, distribution, metabolism, or excretion.
  • Subjects with radiation exposure above acceptable levels
  • Pregnancy

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 90 Years

Are Healthy Volunteers Accepted for this Clinical Trial: Accepts Healthy Volunteers

Clinical Trial Investigator Information

  • Lead Sponsor
    • Institute for Neurodegenerative Disorders
  • Provider of Information About this Clinical Study
    • Principal Investigator: Danna Jennings, MD, Danna Jennings, MD – Institute for Neurodegenerative Disorders
  • Overall Official(s)
    • Danna Jennings, MD, Principal Investigator, Institute for Neurodegenerative Disorders

Source

Clinical Trials content is provided directly by the US National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of information about a specific clinical trial contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01462708